Stem cell transplantation in adult ALL patients

Best Practice and Research: Clinical Haematology

Volumn 15, Issue 4, 2002, Pages 653-674

  Avivi, I ^a   Rowe, J M ^b   Goldstone, A H ^a  

^a UNIVERSITY COLLEGE LONDON HOSPITALS   (United Kingdom)

^b Carmel Medical Centre   (Israel)

Author keywords

Acute lymphocytic leukaemia; Allogeneic stem cell transplantation

Indexed keywords

ANTINEOPLASTIC AGENT; ANTISENSE OLIGONUCLEOTIDE; BUSULFAN; CD20 ANTIGEN; CYCLOPHOSPHAMIDE; ETOPOSIDE; IMATINIB; IMMUNOSUPPRESSIVE AGENT; MELPHALAN; MONOCLONAL ANTIBODY; PROTEASOME INHIBITOR; PROTEIN TYROSINE KINASE INHIBITOR; BCR ABL PROTEIN; PROTEIN P190;

ACUTE LYMPHOCYTIC LEUKEMIA; ADOPTIVE IMMUNOTHERAPY; AGE; ALLOGENIC BONE MARROW TRANSPLANTATION; ALLOTRANSPLANTATION; AUTOLOGOUS BONE MARROW TRANSPLANTATION; BONE MARROW TOXICITY; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER MORTALITY; CANCER PATIENT; CANCER REGRESSION; CANCER RESISTANCE; CANCER SURVIVAL; CLINICAL TRIAL; DRUG EFFICACY; DRUG MEGADOSE; FREQUENCY ANALYSIS; GRAFT VERSUS HOST REACTION; GRAFT VERSUS LEUKEMIA EFFECT; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HIGH RISK PATIENT; HLA MATCHING; HUMAN; IMMUNE RESPONSE; IMMUNOSUPPRESSIVE TREATMENT; INTERMETHOD COMPARISON; LIVING DONOR; MAINTENANCE THERAPY; MINIMAL RESIDUAL DISEASE; MOLECULAR BIOLOGY; PATIENT SELECTION; PHILADELPHIA 1 CHROMOSOME; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZATION; RECURRENCE RISK; REVIEW; SIBLING; SURVIVAL TIME; TREATMENT FAILURE; TREATMENT INDICATION; TREATMENT OUTCOME; WHOLE BODY RADIATION; ACUTE GRANULOCYTIC LEUKEMIA; ADVANCED CANCER; ALLOGENEIC STEM CELL TRANSPLANTATION; AUTOLOGOUS STEM CELL TRANSPLANTATION; CANCER RELAPSE; CANCER RISK; CHROMOSOME TRANSLOCATION; DIAGNOSTIC ACCURACY; HEMATOPOIETIC STEM CELL; NONHUMAN; ORGAN DONOR; PERIPHERAL BLOOD STEM CELL; POLYMERASE CHAIN REACTION; STEM CELL TRANSPLANTATION; T CELL DEPLETION;

EID: 0036950005     PISSN: 15216926     EISSN: None     Source Type: Journal    
DOI: 10.1053/beha.2003.0232     Document Type: Review

References (98)

1. Hoelzer D, Thiel E, Loffler H et al. Prognostic factors in a multicenter study for treatment of acute lymphoblastic leukemia in adults. Blood 1988; 71: 123-131.
2. Rowe JM, Richards SM, Burnett AK et al. Favorable results of allogeneic bone marrow transplantation (BMT) for adults with Philadelphia (Ph)-chromosome-negative acute lymphoblastic leukemia (ALL) in first complete remission (CR): results from the International ALL Trial (MRC UKALL XII/ECOG E2993). Blood 2001; 98: 481a.
3. Schauer P, Zalmen AA, Mertelsmann R et al. Treatment of acute lymphoblastic leukemia in adults: results of the L-10 and L-10M protocols. Journal of Clinical Oncology 1983; 1: 462-470.
4. Sanchez-Fayos J, Outeirino J, Villalobos E et al. Acute lymphoblastic leukaemia in adults: results of a 'total therapy' program in 47 patients over 15 years old. British Journal of Haematology 1985; 59: 689-696.
5. Marcus RE, Catoversusky D, Johnson SA et al. Adult acute lymphoblastic leukaemia: a study of prognostic features and response to treatment over a ten year period. British Journal of Haematology 1989; 73: 2051-2066.
6. Copelan EA & McGuire EA. The biology and treatment of acute lymphoblastic leukemia in adults. Blood 1995; 85: 1151-1168.
7. Larson RA, Dodge RK, Burns CP et al. A five-drug remission induction regimen with intensive consolidation for adults with acute lymphoblastic leukemia: cancer and leukemia group B study 8811. Blood 1995; 85: 2025-2037.
8. Gaynor J, Chapman D, Little D et al. A cause-specific hazard rate analysis of prognostic factors among 199 adults with acute lymphoblastic leukemia. The Memorial Hospital experience since 1969. Journal of Clinical Oncology 1988; 6: 1014-1030.
9. Bloomfield CD, Goldman AI, Alimena G et al. Chromosomal abnormalities identify high-risk and low-risk patients with acute lymphoblastic leukemia. Blood 1986; 67: 415-420.
10. Hussein KK, Dahlberg S, Head E et al. Treatment of acute lymphoblastic leukemia in adults with intensive induction consolidation and maintenance chemotherapy. Blood 1989; 73: 57-63.
11. Champlin R & Gale RP. Acute lymphoblastic leukemia: recent advances in biology and therapy. Blood 1989; 73: 2051-2066.
12. Mortuza FY, Papaioannou M, Moreira IM et al. Minimal residual disease tests provide an independent predictor of clinical outcome in adult acute lymphoblastic leukemia. Journal of Clinical Oncology 2002; 20: 1094-1104.
13. Doney K, Fisher LD, Appelbaum FR et al. Treatment of adult acute lymphoblastic leukemia with allogeneic bone marrow transplantation. Multivariate analysis of factors affecting acute graft-versus-host disease, relapse, and relapse-free survival. Bone Marrow Transplantation 1991; 7: 453-459.
14. Weiden PL, Flournoy N, Thomas ED et al. Antileukemic effect of graft-versus-host disease in human recipients of allogeneic-marrow grafts. New England Journal of Medicine 1979; 300: 1068-1073.
15. Lee S, Kim DW, Kim YJ et al. Influence of karyotype on outcome of allogeneic bone marrow transplantation for adults with precursor B-lineage acute lymphoblastic leukaemia in first or second remission. British Journal of Haematology 2002; 117: 109-118.
16. Barrett AJ, Joshi R, Kendra JR et al. Prediction and prevention of relapse of acute lymphoblastic leukemia after bone marrow transplantation. British Journal of Haematology 1986; 64: 179-186.
17. Campana D & Coustan-Smith E. Advances in the immunological monitoring of childhood acute lymphoblastic leukaemia. Baillière's Clinical Haematology 2002; 15: 1-20.
18. Cave H & van der Werff ten Bosch J et al. Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia. European Organization for Research and Treatment of Cancer - Childhood Leukemia Cooperative Group. New England Journal of Medicine 1998; 339: 591-598.
19. van Dongen JJ, Seriu T, Panzer-Grumayer ER et al. Prognostic value of minimal residual disease in acute lymphoblastic leukaemia in childhood. Lancet 1998; 352: 1731-1738.
20. Brisco J, Hughes E, Neoh SH et al. Relationship between minimal residual disease and outcome in adult acute lymphoblastic leukemia. Blood 1996; 87: 5251-5256.
21. Knechtli CJ, Goulden NJ, Hancock JP et al. Minimal residual disease status before allogeneic bone marrow transplantation is an important determinant of successful outcome for children and adolescents with acute lymphoblastic leukemia. Blood 1998; 92: 4072-4079.
22. Fefer A, Einstein AB, Thomas ED et al. Bone-marrow transplantation for hematologic neoplasia in 16 patients with identical twins. New England Journal of Medicine 1974; 290: 1389-1393.
23. Thomas ED, Buckner CD, Banaji M et al. One hundred patients with acute leukemia treated by chemotherapy, total body irradiation, and allogeneic marrow transplantation. Blood 1977; 49: 511-533.
24. Chester SJ, Esparza AR, Flinton LJ et al. Further development of a successful protocol of graft versus leukemia without fatal graft-versus-host disease in AKR mice. Cancer Research 1977; 37: 3494-3496.
25. Horowitz MM, Gale RP, Sondel PM et al. Graft-versus-leukemia reactions after bone marrow transplantation. Blood 1990; 75: 555-562.
26. Appelbaum FR. Graft versus leukemia (GVL) in the therapy of acute lymphoblastic leukemia (ALL). Leukaemia 1997; 11 (supplement 4): S15-S17.
27. Thomas ED. The use and potential of bone marrow allograft and whole-body irradiation in the treatment of leukemia. Cancer 1982; 50: 1449-1454.
28. Vitale V, Bacigalupo A, van Lint MT et al. Fractionated total body irradiation in marrow transplantation for leukaemia. British Journal of Haematology 1983: 55; 547-554.
29. Tutschka PJ, Copelan EA & Klein JP. Bone marrow transplantation for leukemia following a new busulfan and cyclophosphamide regimen. Blood 1987; 70: 1382-1388.
30. Blume KG, Kopecky KJ, Henslee-Downey JP et al. A prospective randomized comparison of total body irradiation-etoposide versus busulfan-cyclophosphamide as preparatory regimens for bone marrow transplantation in patients with leukemia who were not in first remission: a Southwest Oncology Group study. Blood 1993; 81: 2187-2193.
31. Davies SM, Ramsay NK, Klein JP et al. Comparison of preparative regimens in transplants for children with acute lymphoblastic leukemia. Journal of Clinical Oncology 2000; 18: 340-347.
32. Blaise D, Gaspard MH, Stoppa AM et al. Allogeneic or autologous bone marrow transplantation for acute lymphoblastic leukemia in first complete remission. Bone Marrow Transplantation 1990; 5: 7-12.
33. Sebban C, Lepage E, Vernant JP et al. Allogeneic bone marrow transplantation in adult acute lymphoblastic leukemia in first complete remission: a comparative study. French Group of Therapy of Adult Acute lymphoblastic leukemia. Journal of Clinical Oncology 1994; 12: 2580-2587.
34. Bieri S, Helg C, Chapuis B & Miralbell R. Total body irradiation before allogeneic bone marrow transplantation: is more dose better? International Journal of Radiation Oncology Biology and Physics 2001; 49: 1071-1077.
35. Blume KG, Forman SJ, Snyder DS et al. Allogeneic bone marrow transplantation for acute lymphoblastic leukemia during first complete remission. Transplantation 1987; 43: 389-392.
36. Vernant JP, Marit G, Maraninchi D et al. Allogeneic bone marrow transplantation in adults with acute lymphoblastic leukemia in first complete remission. Journal of Clinical Oncology 1988; 6: 227-231.
37. Barrett AJ, Horowitz MM, Gale RP et al. Marrow transplantation for acute lymphoblastic leukemia: factors affecting relapse and survival. Blood 1989; 74: 862-871.
38. Chao NJ, Forman SJ, Schmidt GM et al. Allogeneic bone marrow transplantation for high-risk acute lymphoblastic leukemia during first complete remission. Blood 1991; 78: 1923-1927.
39. Vey N, Blaise D, Stoppa AM et al. Bone marrow transplantation in 63 adult patients with acute lymphoblastic leukemia in first complete remission. Bone Marrow Transplantation 1994; 14: 383-388.
40. de Witte T, Awwad B, Boezeman J et al. Role of allogeneic bone marrow transplantation in adolescent or adult patients with acute lymphoblastic leukemia or lymphoblastic lymphoma in first remission. Bone Marrow Transplantation 1994; 14: 767-774.
41. Horowitz MM, Messerer D, Hoelzer D et al. Chemotherapy compared with bone marrow transplantation for adults with acute lymphoblastic leukemia in first remission. Annals of Internal Medicine 1991; 115: 13-18.
42. Fiere D, Lepage E, Sebban C et al. Adult acute lymphoblastic leukemia: a multicentric randomized trial testing bone marrow transplantation as postremission therapy. The French Group on Therapy for adult acute lymphoblastic leukemia. Journal of Clinical Oncology 1993; 11: 1990-2001.
43. Attal M, Blaise D, Marit G et al. Consolidation treatment of adult acute lymphoblastic leukemia: a prospective, randomized trial comparing allogeneic versus autologous bone marrow transplantation and testing the impact of recombinant interleukin-2 after autologous bone marrow transplantation. BGMT Group. Blood 1995 August 15; 86(4): 1619-1628.
44. Fiere D, Sebban C & Reiffers J. Comparison of allogeneic transplantation, autologous transplantation and chemotherapy as post induction treatment in adult acute lymphoblastic (ALL) (LALA87 protocol). Proceedings of the American Society of Clinics 1998; 17: 54a.
45. Thiebaut A, Vernant JP, Degos L et al. Adult acute lymphocytic leukemia study testing chemotherapy and autologous and allogeneic transplantation. A follow-up report of the French protocol LALA 87. Hematology and Oncology Clinics of North America 2000; 14: 1353-1366.
46. Oh H, Gale RP, Zhang MJ et al. Chemotherapy versus HLA-identical sibling bone marrow transplants for adults with acute lymphoblastic leukemia in first remission. Bone Marrow Transplantation 1998; 22: 253-257.
47. Paciucci PA, Keaveney C, Cuttner J & Holland JF. Mitoxantrone, vincristine, and prednisone in adults with relapsed or primarily refractory acute lymphocytic leukemia and terminal deoxynucleotidyl transferase positive blastic phase chronic myelocytic leukemia. Cancer Research 1987; 47: 5234-5237.
48. Freund M, Diedrich H, Ganser A et al. Treatment of relapsed or refractory adult acute lymphocytic leukemia. Cancer 1992; 69: 709-716.
49. Weiss MA. Treatment of adult patients with relapsed or refractory acute lymphoblastic leukaemia (ALL). Leukaemia 1997; 11(supplement 4): S28-S30.
50. Welborn JL. Impact of reinduction regimens for relapsed and refractory acute lymphoblastic leukemia in adults. Amercian Journal of Hematology 1994; 45: 341-344.
51. Herzig RH, Bortin MM, Barrett AJ et al. Bone-marrow transplantation in high-risk acute lymphoblastic leukaemia in first and second remission. Lancet 1987; i: 786-789.
52. Bortin MM, Barrett AJ, Horowitz MM et al. Progress in allogeneic bone marrow transplantation for acute lymphoblastic leukemia in the 1980's: a report from the IBMTR. The International Bone Marrow Transplant Registry. Leukemia 1992; 6(supplement 2): 196-197.
53. Thomas DA, Kantarjian H, Smith TL et al. Primary refractory and relapsed adult acute lymphoblastic leukemia: characteristics, treatment results, and prognosis with salvage therapy. Cancer 1999; 86: 1216-1230.
54. Forman SJ. The role of allogeneic bone marrow transplantation in the treatment of high-risk acute lymphocytic leukemia in adults. Leukaemia 1997; 11 (supplement 4): S18-S19.
55. Kersey JH, Weisdorf D, Nesbit ME et al. Comparison of autologous and allogeneic bone marrow transplantation for treatment of high-risk refractory acute lymphoblastic leukemia. New England Journal of Medicine 1987; 317: 461-467.
56. Fleming DR, Henslee-Downey PJ, Romond EH et al. Allogeneic bone marrow transplantation with T cell-depleted partially matched related donors for advanced acute lymphoblastic leukemia in children and adults: a comparative matched cohort study. Bone Marrow Transplantation 1996; 17: 917-922.
57. Gratwohl A & Gahrton G. Allogeneic bone marrow transplantation in leukemia. Acta Oncologica 1988; 27: 557-565.
58. Wingard JR, Piantadosi S, Santos GW et al. Allogeneic bone marrow transplantation for patients with high-risk acute lymphoblastic leukemia. Journal of Clinical Oncology 1990; 8: 820-830.
59. Biggs JC, Horowitz MM, Gale RP et al. Bone marrow transplants may cure patients with acute leukemia never achieving remission with chemotherapy. Blood 1992; 80: 1090-1093.
60. Forman SJ, Schmidt GM, Nademanee AP et al. Allogeneic bone marrow transplantation as therapy for primary induction failure for patients with acute leukemia. Journal of Clinical Oncology 1991; 9: 1570-1574.
61. Zhang MJ, Hoelzer D, Horowitz MM et al. Long-term follow-up of adults with acute lymphoblastic leukemia in first remission treated with chemotherapy or bone marrow transplantation. The Acute Lymphoblastic Leukaemia Working Committee. Annals of Internal Medicine 1995; 123: 428-431.
62. Bensinger WI, Martin PJ, Storer B et al. Transplantation of bone marrow as compared with peripheral-blood cells from HLA-identical relatives in patients with hematologic cancers. New England Journal of Medicine 2001; 344: 175-181.
63. Champlin RE, Schmitz N, Horowitz MM et al. Blood stem cells compared with bone marrow as a source of hematopoietic cells for allogeneic transplantation. IBMTR Histocompatibility and Stem Cell Sources Working Committee and the European Group For Blood And Marrow Transplantation (EBMT). Blood 2000; 95: 3702-3709.
64. Marks DI, Bird JM, Cornish JM et al. Unrelated donor bone marrow transplantation for children and adolescents with Philadelphia-positive acute lymphoblastic leukemia. Journal of Clinical Oncology 1998; 16: 931-936.
65. Vettenranta K, Saarinen-Pihkala UM, Cornish J et al. Pediatric marrow transplantation for acute leukemia using unrelated donors and T-replete or -depleted grafts: a case-matched analysis. Bone Marrow Transplantation 2000; 25: 395-399.
66. Martino R, Sergio G, Maria Dolores Caballero et al. Allogeneic hematopoietic stem cell transplantation with reduced intensity conditioning in acute lymphoblastic leukemia. Blood 2002.
67. Ruggeri L, Capanni M, Casucci M et al. Role of natural killer cell alloreactivity in HLA-mismatched hematopoietic stem cell transplantation. Blood 1999; 94: 333-339.
68. Volpi I, Perruccio K, Tosti A et al. Postgrafting administration of granulocyte colony-stimulating factor impairs functional immune recovery in recipients of human leukocyte antigen haplotype-mismatched hematopoietic transplants. Blood 2001; 97: 2514-2521.
69. Aversa F, Tabilio A, Velardi A et al. Full haplotype mismatched transplant in high risk acute leukemia patients. Blood 2001; 98: 669a.
70. Wiesdorf D, Cairo M, Dharan B et al. ABMTR/NMDP Writing Committee. Autologous versus allogeneic unrelated donor leukemia. Blood 2000; 96: 413a.
71. Davies SM, Kollman C, Anasetti C et al. Engraftment and survival after unrelated-donor bone marrow transplantation: a report from the national marrow donor program. Blood 2000; 96: 4096-4102.
72. Oudshoorn M, van Leeuwen A, vd Zanden HG & van Rood JJ. Bone marrow donors worldwide. Bone Marrow Transplantation 1993; 11 (supplement 1): 35-37.
73. Weisdorf DJ, Nesbit ME & Ramsay NK. Allogeneic bone marrow transplantation for acute lymphoblastic leukemia in remission: prolonged survival associated with acute graft-versus-host disease. Journal of Clinical Oncology 1987; 5: 1348-1355.
74. Jandula BM, Nomdedeu J, Marin P & Vivancos P. Rituximab can be useful as treatment for minimal residual disease in bcr-abl-positive acute lymphoblastic leukemia. Bone Marrow Transplantation 2001; 27: 225-227.
75. Jendreyko N, Bernt K, Gaedicke G et al. Antitumour activity of calicheamicin Q, doxorubicin and anti-CD19 immunoconjugates in a human pre-B ALL cell line. Blood 2001; 98: 105a.
76. Schaap N, Schattenberg A, Bar B et al. Induction of graft-versus-leukemia to prevent relapse after partially lymphocyte-depleted allogeneic bone marrow transplantation by pre-emptive donor leukocyte infusions. Leukaemia 2001; 5: 1339-1346.
77. Jensen M, Tan G, Forman S et al. CD20 is a molecular target for scFvFc:zeta receptor redirected T cells: implications for cellular immunotherapy of CD20+ malignancy. Biology of Blood and Marrow Transplantation 1998; 4: 75-83.
78. Snyder DS. Allogeneic stem cell transplantation for Philadelphia chromosome-positive acute lymphoblastic leukemia. Biology of Blood and Marrow Transplantation 2000; 6: 597-603.
79. Frassoni F, Barrett AJ, Granena A et al. Relapse after allogeneic bone marrow transplantation for acute leukemia: a survey by the E.B.M.T. of 117 cases. British Journal of Haematology 1988; 70: 317-320.
80. Mortimer J, Blinder MA, Schulman S et al. Relapse of acute leukemia after marrow transplantation: natural history and results of subsequent therapy. Journal of Clinical Oncology 1989; 7: 50-57.
81. Bosi A, Laszlo D, Labopin M et al. Second allogeneic bone marrow transplantation in acute leukemia: results of a survey by the European Cooperative Group for Blood and Marrow Transplantation. Journal of Clinical Oncology 2001; 19: 3675-3684.
82. Kishi K, Takahashi S, Gondo H et al. Second allogeneic bone marrow transplantation for post-transplant leukemia relapse: results of a survey of 66 cases in 24 Japanese institutes. Bone Marrow Transplantation 1997; 19: 461-466.
83. Collins RH Jr, Goldstein S, Giralt S et al. Donor leukocyte infusions in acute lymphocytic leukemia. Bone Marrow Transplantation 2000; 26: 511-516.
84. Sanchez J, Serrano J, Gomez P et al. Clinical value of immunological monitoring of minimal residual disease in acute lymphoblastic leukaemia after allogeneic transplantation. British Journal of Haematology 2000; 116: 686-694.
85. Secker-Walker LM, Craig JM, Hawkins JM & Hoffbrand AV. Philadelphia positive acute lymphoblastic leukemia in adults: age distribution, BCR breakpoint and prognostic significance. Leukaemia 1991; 5: 196-199.
86. Heisterkamp N, Stephenson JR, Groffen J et al. Localization of the c-ab1 oncogene adjacent to a translocation breaks point in chronic myelocytic leukemia. Nature 1983; 306: 239-242.
87. Forman SJ, O'Donnell MR, Nademanee AP et al. Bone marrow transplantation for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia. Blood 1987; 70: 587-588.
88. Barrett AJ, Horowitz MM, Ash RC et al. Bone marrow transplantation for Philadelphia chromosome-positive acute lymphoblastic leukemia. Blood 1992; 79: 3067-3070.
89. Chao NJ, Blume KG, Forman SJ & Snyder DS. Long-term follow-up of allogeneic bone marrow recipients for Philadelphia chromosome-positive acute lymphoblastic leukemia. Blood 1995; 85: 3353-3354.
90. Snyder DS, Nademanee AP, O'Donnell MR et al. Long-term follow-up of 23 patients with Philadelphia chromosome-positive acute lymphoblastic leukemia treated with allogeneic bone marrow transplant in first complete remission. Leukaemia 1999; 13: 2053-2058.
91. +) acute lymphoblastic leukemia (ALL). Results from the International ALL Trial (MRC UKALLXII/ECOG E2993). Blood 2001; 98: 856a, abstract.
92. Cornelissen JJ, Carston M, Kollman C et al. Unrelated marrow transplantation for adult patients with poor-risk acute lymphoblastic leukemia: strong graft-versus-leukemia effect and risk factors determining outcome. Blood 2001; 97: 1572-1577.
93. Konopka JB, Watanabe SM & Witte ON. An alteration of the human c-abl protein in K562 leukemia cells unmasks associated tyrosine kinase activity. Cell 1984; 37: 1035-1042.
94. Hermans A, Heisterkamp N, von Linden M et al. Unique fusion of bcr and c-abl genes in Philadelphia chromosome positive acute lymphoblastic leukemia. Cell 1987; 51: 33-40.
95. Talpaz M, Sawyers CL, Kantarjain H et al. Activity of an ABL specific tyrosine kinase inhibitor in patients with BCR-ABL positive acute leukemia, including chronic myelogenous leukemia in blast crisis. Proceedings of the American Society of Clinical Oncology 2000; 19: 4a.
96. Ottmann OG, Sawyers C, Drucker B et al. The International STI571 Study Group, A Phase 12 study to determine the safety and anti-leukemic effects of STI571 in adult patients with Philadelphia chromosome positive acute leukemia. Blood 2000; 96: 828a.
97. Uckun FM, Messinger Y, Chen CL et al. Treatment of therapy-refractory B-lineage acute lymphoblastic leukemia with an apoptosis-inducing CD19-directed tyrosine kinase inhibitor. Clinical Cancer Research 1999; 5: 3906-3913.
98. An WG, Hwang SG, Trepel JB & Blagosklonny MV. Protease inhibitor-induced apoptosis: accumulation of wt p53, p21WAFI/CIP1, and induction of apoptosis are independent markers of proteasome inhibition. Leukemia 2001; 14: 1276-1283.